Brodalumab-Induced Eczematous Reactions in Psoriasis Patients: Management With Switching to Risankizumab.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of cutaneous medicine and surgery"
DOI: 10.1177/12034754231167140
Abstract: Biological treatments targeting IL-17 are highly efficacious with rapid onset of action in psoriasis. Cutaneous adverse events are associated with different biological treatments, including paradoxical psoriasis and eczematous reactions. Brodalumab was previously suggested as an… read more here.
Keywords: switching risankizumab; eczematous reactions; brodalumab induced; induced eczematous ... See more keywords